Skip to main content

Table 2 Methylation and expression levels of C9orf72

From: Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers

 

Groups

P-Values

Variable

C9Plus

C9Minus

Control

Groupsa

C9Plus vs C9Minusb

C9Plus vs Controlb

C9Minus vs Controlb

Methylation, median (IQR), %

4.05 (1.10–17.95)

0.24 (0.15–0.33)

0.46 (0.14–0.75)

4.45e-15

1.70e-13

3.33e-07

0.17

Total, median (IQR), %

73.32 (65.96–86.20)

110.70 (93.68–132.88)

100.00 (87.48–111.27)

2.06e-07

3.67e-07

9.08e-05

0.13

Variant 1, median (IQR), %

55.66 (48.14–72.82)

80.10 (70.31–94.64)

100.00 (74.87–110.67)

1.07e-05

2.83e-04

3.65e-05

0.06

Variant 2, median (IQR), %

61.97 (55.23–73.67)

104.75 (85.86–139.38)

100.00 (90.04–120.12)

9.66e-08

3.43e-07

1.10e-05

0.76

Intron 1a, median (IQR), %

411.20 (244.09–637.62)

263.06 (103.15–398.10)

100.00 (37.09–290.55)

8.40e-04

0.01

4.03e-04

0.13

Intron 1b, median (IQR), %

61.18 (54.37–90.30)

98.61 (75.58–109.73)

100.00 (67.11–130.03)

0.003

0.002

0.01

0.48

  1. C9Plus patients with a C9orf72 repeat expansion, C9Minus patients without this expansion, Control control subjects without a neurodegenerative disease, IQR interquartile range
  2. aA Kruskal-Wallis rank sum test is performed to determine whether a significant difference exists between groups for each of the six variables: levels of C9orf72 promoter methylation (Methylation), total C9orf72 transcripts (Total), variant 1 transcripts (Variant 1), variant 2 transcripts (Variant 2), intron 1a containing transcripts (Intron 1a), and intron 1b containing transcripts (Intron 1b; p < 0.008 is considered significant after Bonferroni correction)
  3. bA Wilcoxon rank sum test is used when the Kruskal-Wallis test is significant for each of the three pairwise comparisons: C9Plus vs C9Minus, C9Plus vs Control, and C9Minus vs Control (p < 0.017 is considered significant after Bonferroni correction)